IL-40 and IL-41 Levels in Sepsis, Septic Shock, and Healthy Individuals
Launched by MELAHAT YALCIN SOLAK · Apr 30, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two proteins in the blood, called Interleukin-40 (IL-40) and Interleukin-41 (IL-41), to see how they relate to sepsis and septic shock. Sepsis is a serious condition that happens when the body has a strong reaction to an infection, which can lead to serious health issues. Septic shock is a more dangerous form of sepsis that can significantly increase the risk of death. By measuring the levels of these proteins in patients with sepsis and septic shock, and comparing them to healthy individuals, researchers hope to find out if IL-40 and IL-41 can be used as helpful indicators for diagnosing and monitoring these serious conditions.
To be part of this study, participants must be at least 18 years old and either have a clinical diagnosis of sepsis or septic shock or be healthy with no recent infections or chronic inflammatory diseases. Participants will need to provide a blood sample before starting any antibiotic treatment. This trial is not yet recruiting, but if you or someone you know is interested, it's important to understand that the goal is to better understand how these proteins function in the body and how they might help in the treatment of sepsis in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patient Group:
- • Clinical diagnosis of sepsis or septic shock, based on validated diagnostic criteria (e.g., Sepsis-3)
- • Age 18 years or older
- • Ability and willingness to provide a blood sample prior to initiation of antibiotic treatment
- Healthy Control Group:
- • Determined to be in good general health based on physical examination and medical history
- • Age 18 years or older
- • Willingness to provide written informed consent
- Exclusion Criteria:
- * Patient Group:
- • History of chronic inflammatory diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus)
- • Active cancer or current use of immunosuppressive therapy
- • Pregnant or breastfeeding
- • Presence of other serious conditions that may interfere with diagnosis or treatment (e.g., liver failure, chronic kidney disease)
- Healthy Control Group:
- • Recent infection within the past month or use of antibiotics in the last 6 weeks
- • History of chronic inflammatory diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus)
- • Underwent surgery within the past 6 months
- • Conditions that may affect blood parameters, such as recent blood donation or intense physical activity
- • Pregnant or breastfeeding
About Melahat Yalcin Solak
Melahat Yalcin Solak is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative clinical studies. With a focus on ethical practices and regulatory compliance, Melahat Yalcin Solak collaborates with leading researchers and institutions to develop and evaluate new therapies across various therapeutic areas. Leveraging a strong foundation in clinical science and a passion for improving health outcomes, the organization aims to contribute significantly to the understanding and treatment of complex medical conditions, ensuring that patient safety and scientific integrity remain at the forefront of all research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
şanlıurfa, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported